Physician profile
Jene Smith
NPI 1073505418
$3,478.29
in general payments reported to CMS, 2019-2025
32 companies · $49.76 in 2025
The $49.76 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,044 · 2022: $1,003 · 2023: $776 · 2024: $607 · 2025: $49.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,134.70 | 2021-2024 | |
| Novo Nordisk INC | $303.60 | 2021-2025 | Saxenda, Wegovy, Ozempic |
| Pfizer INC. | $185.81 | 2022-2024 | |
| Lilly USA, LLC | $181.29 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $160.31 | 2021-2024 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.47 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $144.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.16 | 2021-2025 | Jardiance |
| Bausch Health US, LLC | $106.95 | 2021-2023 | Aplenzin |
| Nestle Healthcare Nutrition INC. | $105.62 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $81.92 | 2022-2023 | Qelbree |
| Dexcom, INC. | $76.25 | 2021-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $75.58 | 2021-2024 | Trintellix |
| Amgen INC. | $75.08 | 2023-2024 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $72.12 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $59.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $55.37 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $47.14 | 2021 | |
| Astellas Pharma US INC | $40.42 | 2023 | Veozah, Myrbetriq |
| Depuy Synthes Sales INC. | $33.25 | 2021 | |
| Lundbeck LLC | $32.62 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $32.13 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $31.57 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.34 | 2023-2024 | Shingrix, Boostrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $28.50 | 2022-2023 | |
| Edwards Lifesciences Corporation | $21.14 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.77 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.52 | 2024 | Voquezna |
| Almatica Pharma LLC | $17.41 | 2024 | Loreev Xr |
| Esperion Therapeutics, INC. | $14.83 | 2024 | Nexletol |
| Allergan, INC. | $14.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jene Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.